- Previous: Advanced Hepatitis C Infection: Six Tips to Temper Cirrhosis
- Main
- Next: Modern and Traditional Research Expands Knowledge of Liver Disease
Infergen and Ribavirin Trial Brings Renewed Hope to Previous Non-Responders
June 22, 2009
Although their first attempt at Hepatitis C antiviral therapy was unsuccessful, a significant number of previous non-responders achieved a sustained viral response with once-daily Infergen with Ribavirin.
Three Rivers Presents Positive Results For Phase-III Hepatitis C Trial
16-June-2009
By Staff Reporter
Phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures.
Pennsylvania-based Three Rivers Pharmaceuticals has announced positive results from phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures.
Among participants who failed initial treatment with PEG-IFN/RBV, retreatment with Infergen in combination with RBV, yielded sustained virological response rates (as high as 31.6%) in interferon-sensitive patients with low baseline liver fibrosis scores. Overall intent to treat analysis was 6.9% among the 9 mcg/day group and 10.7% in the 15 mcg/day group.
Direct trial, a phase III, randomized, open-label, multicenter, US-based trial was conducted to investigate the efficacy, tolerability, and safety of daily Infergen at dosages of 9 and 15 mcg/day, administered with daily weight-based RBV.
Patients with cirrhosis were less likely to benefit from retreatment with Infergen and RBV, unless they displayed previous interferon sensitivity of at least 1-log drop in viral levels on prior therapy.
Donald Kerrish, President and CEO of Three Rivers Pharmaceuticals, said: "These results represent a significant step forward for HCV patients who deserve a second chance at a potential cure for this chronic viral infection."
---
URL for Article Source:
http://www.pharmaceutical-business-review.com/news/three_rivers_presents_positive_results_for_phaseiii_hepatitis_c_trial_090616
Posted by Editors at June 22, 2009 3:42 PM
Site Topics
HCV Symptoms
You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.
Lab Tests
What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.
Hepatitis C Genotypes
Learn about Hepatitis C Genotypes and their variants.
Viral Load
Includes a convenient Viral Load chart, as well as a link to a detailed discussion on how to analyze and interpret viral load numbers.
What is...?
Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.
HCV Medicines
Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.
Hepatitis C Doctors
A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.
Biopsy Info
A comprehensive resource of information relating to the liver biopsy.
Cirrhosis
Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.
Liver Cancer
Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.
Liver Disease Medicines
An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.
Hep-Central Email List
Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.
HCV Links
Convenient links to other sites external to Hepatitis-Central.
Mother/Child Transmission
Discussions of the special problems and precautions necessary involving mother to child transmission of Hepatitis C.
HCV Natural Remedies
A number of herbal products useful in the management of liver disease.
HCV Books
Recommended reading for those interested in hepatitis information.
Hepatitis C Forum
A Bulletin Board for discussions on hepatitis, treatments, etc.
Hepatitis C Activism
An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.
Advertisement
